Pentoxifylline versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial

Table 5 Progression of scores evaluating the severity of liver disease of patients receiving pentoxifylline (group I) as compared to those receiving prednisolone (group II) in the treatment of severe alcoholic hepatitis (mean ± SD)

Liver disease score	Baseline	Duration of follow-up
		4 wk	3 mo	6 mo	1 yr
Maddrey DF score
Group I1	54.25 ± 16.24	23.29 ± 12.07	14.3 ± 4.53	10.24 ± 4.27	7.79 ± 3.2
Group II2	57.78 ± 17.08	27.82 ± 11.73	15.60 ± 6.21	11.16 ± 3.70	7.27 ± 2.67
P value	0.39	0.15	0.39	0.43	0.94
MELD Score
Group I1	23.14 ± 3.97	15.53 ± 3.63	12.41 ± 2.88	10.37 ± 2.32	9.18 ± 1.59
Group II2	22.65 ± 3.33	17.78 ± 4.56	13.45 ± 2.77	11.14 ± 1.83	9.4 ± 1.88
P value	0.58	0.04	0.20	0.21	0.67
GAHS
Group I1	8.23 ± 1.07	6.37 ± 0.79	6.10 ± 0.77	5.96 ± 0.90	5.74 ± 0.66
Group II2	7.94 ± 0.95	6.52 ± 1.09	5.91 ± 0.61	5.91 ± 0.61	5.7 ± 0.57
P value	0.24	0.56	0.34	0.81	0.83
Child’s score
Group I1	11.85 ± 1.62	9.69 ± 2.57	7.14 ± 1.60	5.96 ± 1.09	5.78 ± 0.89
Group II2	12.15 ± 1.28	9.81 ± 2.08	7.59 ± 1.68	6.23 ± 0.97	5.9 ± 0.79
P value	0.41	0.84	0.33	0.38	0.63

P < 0.05 considered statistically significant.

¹In group I: n = 34 at baseline, n = 32 at 4 wk and n = 29 at 3 mo, n = 27 at 6 mo and 1 year.

²In group II: n = 34 at baseline, n = 27 at 4 wk and n = 22 at 3 mo, 6 mo and n = 20 at 1 year.